Hanmi Pharmaceutical Signs Fabry Disease Drug Licensing Deal With BioMarin
Hanmi Pharmaceutical entered a technology licensing agreement with BioMarin for the Fabry disease treatment LA-GLA.
Related stories
PL Capital Upgrades Hindustan Unilever to Buy
PL Capital upgraded Hindustan Unilever to a Buy rating, citing valuation and growth in consumer stocks.
M impact | EQUITY | Oct 30, 2026, 05:31 AM UTC
Asian session market picture: S&P 500 -0.9%, Nasdaq 100 -1.88%; USD/JPY -0.03%, WTI +0.99%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 0.9 percent, Nasdaq futures is down 1.88 percent, Dow futures is down 0.17 percent and Russell futures is do
M impact | EQUITY | Oct 30, 2026, 05:30 AM UTC
Amazon Capex Reaches $77.3 Billion Last Quarter, Above Expectations
Amazon’s capital expenditure rose 43% sequentially and was $20 billion above expectations, according to the report.
H impact | EQUITY | Oct 30, 2026, 05:16 AM UTC
DJT Shares Trade More Than 2% Lower Overnight
Trump Media & Technology Group shares hit an intraday all-time low of $5.68 on Thursday, closing 3% lower and more than 61% below their annual highs. The stock continued to trade m
M impact | EQUITY | Oct 30, 2026, 05:10 AM UTC
4-PAG to Acquire 51% Stake in Evergrande Property Services
M impact | EQUITY | Oct 30, 2026, 05:07 AM UTC
PAG to Acquire 51% of Evergrande Property Services
PAG will acquire a 51% stake in Evergrande Property Services.
M impact | EQUITY | Oct 30, 2026, 05:07 AM UTC